comparemela.com
Home
Live Updates
NXC-201 Receives Orphan Drug Designation in European Union f
NXC-201 Receives Orphan Drug Designation in European Union f
NXC-201 Receives Orphan Drug Designation in European Union for Multiple Myeloma
The CAR T-cell therapy NXC-201 has received orphan drug designation by the European Commission for patients with multiple myeloma.
Related Keywords
Athens ,
Attikír ,
Greece ,
Ilya Rachman ,
Gabriel Morris ,
Drug Administration ,
Immix Biopharma Inc ,
European Union ,
International Myeloma Society Annual Meeting ,
Nexcella Inc ,
International Myeloma Working Group Uniform Response Criteria ,
European Commission ,
Immix Biopharma ,
International Myeloma Society Annual ,
Single Day ,
Annual Meeting ,
Myeloma Society Annual Meeting ,
Nxc 201 Receives Orphan Drug Designation ,
Nxc 201 ,
Multiple Myeloma ,